FDA Approves Genentech’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization

Article Link: FDA Approves Genentech’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization



Source: FDA New Drug Approvals